Prosecution Insights
Prosecution Insights
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §112 only | 1 (20%) |
| Double-patenting only | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GANGLE, BRIAN J | 1 | 76.6% | +15.2% |
| ZEMAN, ROBERT A | 1 | 54.0% | +27.9% |
| DENT, ALANA HARRIS | 1 | 44.3% | +32.1% |
| LI, BAO Q | 1 | 75.5% | +26.4% |
| SKIBINSKY, ANNA | 1 | 39.0% | +28.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17642335 | Method for identifying T-cell epitopes | SKIBINSKY, ANNA | 8d overdue |
| 17786631 | Nucleic acid vaccination using neo-epitope encoding constructs | LI, BAO Q | 3d overdue |
| 18732821 | Proteins and nucleic acids useful in vaccines targeting Pseudomonas aeruginosa | ZEMAN, ROBERT A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17642335 | Method for identifying T-cell epitopes | SKIBINSKY, ANNA | 8d overdue |
| 17786631 | Nucleic acid vaccination using neo-epitope encoding constructs | LI, BAO Q | 3d overdue |
| 18999335 | Proteins and nucleic acids useful in vaccines targeting Klebsiella pneumoniae | GANGLE, BRIAN J | — |
| 18732821 | Proteins and nucleic acids useful in vaccines targeting Pseudomonas aeruginosa | ZEMAN, ROBERT A | — |
| 17995601 | Neoepitope immunotherapy with APC targeting unit | DENT, ALANA HARRIS | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1643 | 1 |
| 1671 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18999335 | Proteins and nucleic acids useful in vaccines targeting Klebsiella pneumoniae | GANGLE, BRIAN J | — | §112 | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18732821 | Proteins and nucleic acids useful in vaccines targeting Pseudomonas aeruginosa | ZEMAN, ROBERT A | 1645 | §102§103§112 | Non-Final OA | — | Pending | Jun 04, 2024 |
| 17995601 | Neoepitope immunotherapy with APC targeting unit | DENT, ALANA HARRIS | 1643 | DP | Final Rejection | — | Pending | Oct 06, 2022 |
| 17786631 | Nucleic acid vaccination using neo-epitope encoding constructs | LI, BAO Q | 1671 | §103§112 | Final Rejection | 3d overdue | Pending | Jun 17, 2022 |
| 17642335 | Method for identifying T-cell epitopes | SKIBINSKY, ANNA | 1635 | §101§103§112 | Non-Final OA | 8d overdue | Pending | Mar 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial